The IL-33/ST2 signaling pathway plays a dual, environment-dependent role in tumor development, modulating tumor-related immunity by remodeling the TME to either promote immunosuppressive cell recruitment or inhibit tumor growth by enriching NK and cytotoxic T cells. The gene discussed is IL1RL1; the disease is neoplasm.